4//SEC Filing
INFINITY PHARMACEUTICALS, INC. 4
Accession 0001181431-06-052824
CIK 0001113148operating
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 8:01 PM ET
Size
21.4 KB
Accession
0001181431-06-052824
Insider Transaction Report
Form 4
Moss Franklin
Director
Transactions
- Award
Stock Option (right to buy)
2006-09-12+2,210→ 2,210 totalExercise: $3.48Exp: 2016-09-12→ Common Stock (2,210 underlying) - Award
Common Stock
2006-09-12+9,818→ 9,818 total - Award
Common Stock
2006-09-12+33,154→ 33,154 total - Award
Common Stock
2006-09-12+5,663→ 5,663 total - Award
Common Stock
2006-09-12+7,491→ 7,491 total - Award
Stock Option (right to buy)
2006-09-12+28,125→ 28,125 totalExercise: $15.04Exp: 2016-09-12→ Common Stock (28,125 underlying) - Award
Common Stock
2006-09-12+3,683→ 3,683 total(indirect: By Trust)
Footnotes (13)
- [F1]Reflects a 1-for-4 reverse stock split, which became effective on September 12, 2006.
- [F10]The option vests as to 552 shares on June 12, 2006, 184 shares on June 30, 2006 and the remainder in equal monthly installments through February 2007.
- [F11]Received in the Merger in exchange for a stock option to acquire 10,000 shares of IPI Common Stock for $0.77 per share based on a conversion ratio of 0.88411.
- [F12]The exercise price reflects the exercise price of each option to purchase IPI common stock prior to the closing of the Merger divided by a conversion ratio of 0.88411, as adjusted to reflect the 1-for-4 reverse stock split.
- [F13]The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]Received in exchange for 25,625 shares of Infinity Discovery, Inc. ("IPI") common stock in connection with the merger of IPI into Infinity Pharmaceuticals, Inc. (the "Merger") based on a conversion ratio of 0.88411.
- [F3]Received in exchange for 50,000 shares of IPI Series A Preferred Stock in connection with the Merger based on a conversion ratio of 0.78550. The Series A Preferred Stock had no expiration date.
- [F4]Received in exchange for 26,667 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F5]Received in exchange for 150,000 shares of IPI Common Stock in connection with the Merger based on a conversion ratio of 0.88411. These shares are held by Franklin H. Moss and Kimberly S. Moss, JTWROS.
- [F6]Received in exchange for 16,667 shares of IPI Common Stock in connection with the Merger based on a conversion ratio of 0.88411.
- [F7]Received in exchange for 16,667 shares of IPI Common Stock in connection with the Merger based on a conversion ratio of 0.88411.
- [F8]Received in exchange for 16,666 shares of IPI Common Stock in connection with the Merger based on a conversion ratio of 0.88411.
- [F9]The option vests as to 9,375 of the shares on the first anniversary of the grant date, which grant date was September 12, 2006, and the remainder in quarterly installments of 2,343 shares beginning at the end of the first quarter thereafter, provided that the holder continues to serve as a director.
Documents
Issuer
INFINITY PHARMACEUTICALS, INC.
CIK 0001113148
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001113148
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 8:01 PM ET
- Size
- 21.4 KB